Results demonstrated that high expressions of PCDHGA7, PCDHB12, PCDHAC2, PCDHA11, and ITGA5 were associated with poor OS outcome in CC patients, but ITGA2B, DGCR6, VCAM1, CD6, and PIK3R2 were protective factors. Here, PCDHAC2 is linked to cholangiocarcinoma.